The Acetylcholine Hypothesis: How The Cholinergic System Became The First Target For Alzheimer’S Drugs

The Cholinergic Hypothesis: How One Idea Changed the Way We Think About Alzheimer’s Forever

Picture the year 1976. There is no MRI scanner in routine clinical use, no genetic testing, no amyloid imaging. Alzheimer’s disease is still widely considered a rare and unusual form of premature senility, an outlier, not the epidemic it would become. And yet, in a handful of university laboratories, something extraordinary is beginning to take shape. Scientists examining the post-mortem brains of Alzheimer’s patients are noticing a striking, consistent pattern: the neurons that produce acetylcholine, the brain’s key chemical messenger for memory and attention, are dying. Not randomly. Not incidentally. They are dying *first*, and dying *hard*, in a region of the brain called the nucleus basalis of Meynert.

That observation would ignite one of the most consequential hypotheses in the history of neuroscience. It would spawn the world’s first generation of Alzheimer’s drugs. And it would teach us something profound about how memory works, how the brain ages, and what happens when a single neurotransmitter system begins to fail. Here is what nearly five decades of research, drawn from Vitacuity’s analysis of over 1.77 million scientific papers, has taught us about acetylcholine, the cholinergic system, and the long, remarkable journey from laboratory discovery to the clinic.

The Science Behind the Cholinergic Hypothesis

To understand the hypothesis, you first need to understand what acetylcholine actually does.

Acetylcholine (ACh) is one of the brain’s most ancient and important chemical messengers. It is released from specialised nerve cells called cholinergic neurons, travels across the tiny gap between nerve cells (the synapse), and binds to receptors on the receiving cell, triggering a response. Think of it as a key fitting a lock. When that process works smoothly, your brain can form new memories, sustain focused attention, make decisions, and learn. When it breaks down, all of those abilities begin to fade [5].

The cholinergic system in the brain is organised like a broadcasting network. The main transmission towers are clusters of neurons in the basal forebrain, a region deep in the brain that sends projections across wide territories of the cortex and hippocampus, the areas most critical for memory [6]. The most important of these clusters is a structure called the nucleus basalis of Meynert. Lose the neurons there, and you lose the signal to enormous swathes of the thinking brain [1].

Acetylcholine itself is synthesised inside neurons from two basic ingredients: choline (derived from your diet) and acetyl coenzyme A. This synthesis is controlled by an enzyme called choline acetyltransferase, or ChAT. Once made, acetylcholine is packaged into tiny vesicles and released into the synapse when the neuron fires. After it has done its job, another enzyme, acetylcholinesterase (AChE), rapidly breaks it down, recycling the choline back for future use [3]. This elegant system is the molecular machinery at the heart of the cholinergic hypothesis.

What the researchers of the late 1970s and early 1980s discovered was that in Alzheimer’s disease, this machinery is severely damaged. Post-mortem studies of Alzheimer’s brains consistently showed dramatic losses of ChAT activity in the cerebral cortex, meaning less acetylcholine was being made. They found degeneration of the magnocellular neurons in the nucleus basalis of Meynert. And they found all of this correlated with the severity of cognitive decline the patients had experienced during their lives [1]. The cholinergic hypothesis of Alzheimer’s disease was born: that the progressive loss of these neurons and the resulting deficit of acetylcholine was a primary driver of the memory loss seen in the disease.

From Hypothesis to Drug: The Birth of a New Treatment Paradigm

Evidence grade: Strong for symptomatic benefit; conflicted on long-term disease modification

Once scientists understood the mechanism, the therapeutic logic followed almost immediately. If you are losing acetylcholine, the most direct thing you can do is try to preserve what remains. The enzyme acetylcholinesterase breaks acetylcholine down, so if you block that enzyme, more acetylcholine survives in the synapse for longer. More signal gets through. Cognition improves.

This was the reasoning behind a class of drugs called acetylcholinesterase inhibitors (AChEIs). The first, tacrine, was approved by the US Food and Drug Administration in 1995, making it the first ever drug approved to treat Alzheimer’s disease [12]. Its approval was based on clinical trials showing modest but real symptomatic benefit on cognitive, behavioural, and global measures. Tacrine, however, was hepatotoxic (damaging to the liver) and poorly tolerated. It is no longer used [15].

What came next changed the clinical landscape. Donepezil, rivastigmine, and galantamine were developed through the 1990s and early 2000s, each refining the same core mechanism but with better tolerability, longer half-lives, and more selective action [9]. Of the four drugs currently approved for Alzheimer’s disease worldwide, three are cholinesterase inhibitors [11]. These medications have been through multiple placebo-controlled randomised controlled trials and have regulatory approval internationally, they are the most robustly evidence-based pharmacological treatments in dementia medicine [4].

Donepezil, perhaps the most widely prescribed, works by selectively and reversibly inhibiting AChE, slowing the breakdown of acetylcholine in the synapse. Its pharmacology has been studied in extraordinary detail, including its precise binding interactions with the acetylcholinesterase enzyme at a molecular level [9]. Rivastigmine, notably, is available as a transdermal patch, allowing slow and steady drug release while reducing the gastrointestinal side effects that can accompany oral dosing [4]. Galantamine has the additional property of allosterically modulating nicotinic acetylcholine receptors, essentially making the remaining receptors more sensitive to the acetylcholine that is still present [11].

The important honest caveat here: these drugs produce *symptomatic* improvement, not disease modification. They do not halt the underlying degeneration of cholinergic neurons. They work best when there are still enough functioning cholinergic synapses left to respond, which is why early treatment tends to produce better outcomes than late treatment [1].

The Brain’s Broadcasting Network: What Acetylcholine Actually Controls

Evidence grade: Strong, based on four decades of human pharmacological studies

One of the most valuable contributions of cholinergic research has been the detailed mapping of what acetylcholine actually does in the human brain. This is not merely academic, it explains precisely why the symptoms of Alzheimer’s take the form they do.

Research using pharmacological probes in human volunteers, compounds that either boost or block cholinergic activity in real time, has built a remarkably clear picture [5]. Acetylcholine is involved in:

Attention and arousal. The cholinergic system helps the brain decide what to focus on. Cholinergic disruption degrades the ability to filter out irrelevant information and sustain directed attention, one of the earliest cognitive complaints in Alzheimer’s disease.

Episodic memory and new learning. Acetylcholine is critical for the formation of new memories, particularly in the hippocampus. When cholinergic tone is experimentally reduced (using blocking agents), healthy volunteers show measurable impairments in the encoding of new memories. When it is boosted, memory consolidation improves [5].

Decision-making and working memory. The evidence shows that changes in cholinergic activity produce quantifiable improvements or impairments in decision-making speed and efficiency [5]. This is not a subtle effect, it is demonstrable in controlled experiments with real-time cognitive testing.

Acetylcholine achieves these effects through two families of receptors: muscarinic receptors (of which the M1 subtype is most important for cognition) and nicotinic receptors (particularly the alpha-4 beta-2 subtype, which is concentrated in memory circuits) [6][7]. Amyloid-beta, the protein that accumulates in Alzheimer’s disease, does not merely damage cholinergic neurons; it also directly blocks cholinergic receptors and obstructs the signalling process itself, compounding the deficit [6]. This interplay between amyloid pathology and cholinergic disruption has become one of the central themes of contemporary Alzheimer’s research.

Why Treatment Response Varies: The Integrity Principle

Evidence grade: Promising, small sample size but important mechanistic insight

One of the most clinically significant findings of recent years has been a simple but powerful insight: cholinergic drugs work better when there is more cholinergic system left to work with.

A 2018 study by Richter et al., published in *Brain*, used PET scanning to measure cortical acetylcholinesterase activity in 14 patients with mild cognitive impairment due to Alzheimer’s disease, alongside 16 age-matched healthy controls [13]. Participants underwent functional MRI memory tasks under three conditions: no drug, placebo, and a single dose of rivastigmine (3 mg). The findings were illuminating.

In patients with mild cognitive impairment, rivastigmine improved memory-related neural activation, particularly in the right fusiform gyrus, and restored more normal patterns of brain deactivation in the posterior cingulate cortex. But crucially, the *degree* of response to rivastigmine was directly related to how much acetylcholinesterase activity the patient still had: the more cholinergic system integrity remained, the more the drug could amplify the signal [13].

This finding has profound implications. It suggests that cholinergic treatment is most effective in the *earliest* stages of the disease, before too much of the system has been lost. It also helps explain why clinical trial results for cholinesterase inhibitors have sometimes appeared modest: if a proportion of the participants in any trial have already lost substantial cholinergic capacity, their response will be muted, pulling down average effect sizes. The drug has not failed; the window for its optimal use has been missed [1][13].

The study was small, 30 participants in total, and a single dose of rivastigmine does not replicate the full clinical picture of sustained treatment. But the mechanistic logic is sound and consistent with what we know about the disease’s progression.

The Cholinergic Precursor Story: Why Choline Supplementation Alone Isn’t Enough

Evidence grade: Conflicted, important nuance needed

In the early years of the cholinergic hypothesis, the most intuitive therapeutic idea was precursor loading: if the brain isn’t making enough acetylcholine, why not give it more of the raw materials? Choline, the dietary building block of acetylcholine, was the obvious candidate. Lecithin (phosphatidylcholine) was also tried [8].

The results were disappointing, but the reason why is genuinely interesting and worth understanding. Controlled clinical studies showed no meaningful cognitive benefit from supplementing choline or lecithin directly in Alzheimer’s patients [8]. The metabolic explanation: while free choline does increase the brain’s choline availability, it does not reliably increase acetylcholine *synthesis or release*. For choline to be used for ACh production, it needs to be incorporated and stored into phospholipids within the brain, simply flooding the system with free choline does not trigger the downstream synthesis machinery in a meaningful way.

The story is somewhat different for more complex choline-related compounds. Cytidine 5′-diphosphocholine (CDP-choline) and alpha-glyceryl-phosphorylcholine (choline alfoscerate), molecules involved in choline’s biosynthetic pathways rather than simple free choline, have shown modest improvement in cognitive dysfunction in adult-onset dementia in some controlled studies [8]. These are not dramatic effects, and the research base is not large, but they reflect a more sophisticated understanding: the *form* in which you provide cholinergic precursors matters enormously. The right molecule, reaching the right pathway, can have a different biological effect than the crude starting material.

This is an important lesson in how nutrition and supplementation interact with neurobiology, and it explains why the precursor loading story, while initially dismissed, has not been entirely closed.

The Next Generation: Going Beyond Enzyme Inhibition

Evidence grade: Promising to early stage, ongoing clinical trials

The cholinesterase inhibitor approach has always had a fundamental limitation: it works by conserving acetylcholine that is already being produced, rather than restoring the system that produces it. As Alzheimer’s disease progresses and more cholinergic neurons die, there is less acetylcholine to conserve, and the drugs’ effectiveness diminishes accordingly [1].

This has spurred research into more ambitious cholinergic strategies. Two of the most promising involve targeting the receptors themselves, rather than the enzyme.

Muscarinic receptor agonists, drugs that directly activate the M1 muscarinic receptor, could in theory bypass the dying neurons entirely and stimulate memory circuits directly. They could also potentially exert additional benefits: M1 receptor activation has been shown to reduce amyloid precursor protein processing, potentially slowing one of the upstream pathologies of the disease [6][7].

Nicotinic receptor agonists targeting the alpha-4 beta-2 subtype, which is concentrated in memory and attention circuits, are also under active investigation. Loss of these receptors has been documented using PET and SPECT imaging in Alzheimer’s disease, and their stimulation has shown cognitive benefits in pharmacological studies [7][14].

Nerve growth factor (NGF)-based therapy represents perhaps the most ambitious approach. NGF is described as the “master regulator” of cholinergic neuron survival, it promotes cell survival, increases acetylcholine production, supports regenerative signalling, and maintains anti-inflammatory tone in the basal forebrain [2]. NGF levels are severely depleted in Alzheimer’s disease, and restoring NGF signalling to the cholinergic nuclei of the basal forebrain could, in principle, revive dying neurons rather than simply compensating for their loss. The major challenge has been delivery: NGF cannot cross the blood-brain barrier efficiently. Clinical strategies being explored include direct intracerebral delivery and encapsulated cell biodelivery systems [2]. Results from ongoing clinical studies are awaited.

Cholinergic Imaging: Seeing the System in Action

Evidence grade: Promising, established research methodology, ongoing refinement

One of the most powerful developments in cholinergic research has been the ability to visualise the system in living patients using molecular brain imaging, PET and SPECT scanning with radioligands designed to bind to specific cholinergic targets [14].

Using tracers such as ¹¹C-MP4A and ¹¹C-PMP to tag acetylcholinesterase, researchers have documented significant reductions in cortical AChE activity in Alzheimer’s disease, Parkinson’s disease with dementia, and Parkinson’s disease alone [14]. These reductions correlate with specific cognitive impairments, particularly attention and working memory, providing a direct neurobiological link between the cholinergic deficit and the cognitive symptom.

SPECT imaging with ¹²³I-5IA, which tags the alpha-4 beta-2 nicotinic receptor, has allowed researchers to map receptor loss across the course of dementia [14]. And imaging of the vesicular acetylcholine transporter, the molecule that packages acetylcholine into vesicles for release, has provided another window into cholinergic terminal integrity.

One particularly striking clinical application has emerged from thalamic versus cortical AChE ratios: research suggests this ratio can help differentiate Parkinson’s disease from progressive supranuclear palsy (PSP), two conditions that can look very similar in early presentation [14]. This is the cholinergic hypothesis evolving from a research concept into a precision diagnostic tool.

What We Don’t Know Yet

Fifty years of research is a long time, and the cholinergic hypothesis has taught us an enormous amount. But intellectual honesty requires acknowledging what remains genuinely uncertain.

The cholinergic system is necessary but not sufficient. Acetylcholine deficiency is a consistent and important feature of Alzheimer’s disease, but the disease also involves amyloid plaques, tau protein tangles, neuroinflammation, synaptic loss, and metabolic disruption. The cholinergic hypothesis explains the *symptoms* of cognitive decline powerfully, but the *cause* of the underlying neurodegeneration remains a more complex and contested question [10]. The amyloid cascade hypothesis has dominated drug development for decades, and yet multiple anti-amyloid antibody trials failed before lecanemab and donanemab showed modest disease-modifying effects in recent years [1][10].

Why do some patients respond to cholinesterase inhibitors and others do not? Clinical practice shows wide variation in treatment response. The integrity principle, that response depends on remaining cholinergic capacity, helps explain some of this variation [13], but it is not the complete answer. Genetic variation in cholinergic receptors, differences in the rate of neurodegeneration, and comorbid pathologies all play roles that are not yet fully mapped.

Optimal dosing and timing remains unclear. The clinical trials that established the benefit of cholinesterase inhibitors were not designed to answer questions about optimal dosing trajectories, the ideal point in the disease course to initiate treatment, or how long treatment should continue [4][10]. Real-world prescribing is still guided by imprecise rules of thumb rather than precision protocols.

Precursor and receptor-targeted therapies remain investigational. The more sophisticated cholinergic interventions, NGF delivery, muscarinic agonists, nicotinic agonists, have shown promise in research settings but have not yet produced approved treatments [2][7]. The translation from mechanism to medicine has proven harder than hoped.

The relationship between dietary choline intake, brain acetylcholine levels, and long-term cognitive outcomes in healthy ageing remains incompletely understood. The research on precursor loading in established Alzheimer’s disease is discouraging, but what about decades of adequate versus inadequate choline intake across a lifetime? This remains an important open question [3][8].

The Final Takeaway

Here is what the cholinergic hypothesis has ultimately given us, and what you can actually do with that knowledge today.

First, the scientific gift: the cholinergic hypothesis was not wrong. It was, and remains, one of the most important correct observations in the history of dementia research. The finding that acetylcholine-producing neurons die early and consistently in Alzheimer’s disease has been replicated so many times, in so many populations, that it is among the most robustly established facts in all of neuroscience [1][5]. The drugs it produced, donepezil, rivastigmine, galantamine, are not miracle cures, but they are genuine, evidence-based treatments that have helped millions of patients maintain cognitive function for longer [4][11]. That matters enormously to patients and families.

Second, the nuanced truth about conflicted evidence: when people say “cholinesterase inhibitors have modest effects,” they are technically right but often missing the point. The effect size is modest *on average*, across populations that include both early and late-stage patients, across studies run in different eras with different diagnostic criteria. When treatment is initiated early, in patients with good cholinergic integrity, the benefit can be substantially more meaningful [13]. The lesson here, for medicine generally, is that average effects in heterogeneous populations can obscure the genuine benefit to well-selected patients.

Third, what this means for you, reading this in your 40s, 50s, or 60s: the cholinergic system is not merely a subject for neurologists. It is your memory, your attention, your ability to learn. It is working right now, and it is directly affected by how well you sleep, how much you exercise, what you eat, and, critically, how early you pay attention to early warning signs of cognitive change.

Practical actions grounded in what the science actually supports:

– Dietary choline matters. The brain’s cholinergic system depends on an adequate supply of choline from the diet. Eggs, liver, fish, and legumes are the richest sources. Most people over 50 do not consume optimal amounts. While direct choline supplementation alone has not proven sufficient to treat Alzheimer’s disease, the logic of maintaining adequate cholinergic precursor availability across a lifetime is sound [3][8]. Consider a choline-containing supplement, such as CDP-choline or choline alfoscerate, if your diet is limited. These forms appear metabolically more relevant than simple choline or lecithin [8].

– Protect your cholinergic system by protecting your sleep. The cholinergic system is deeply involved in the regulation of sleep-wake cycles and arousal. Chronic poor sleep is one of the most consistent risk factors for cognitive decline, and there is strong evidence that sleep is when the brain clears the amyloid that directly damages cholinergic neurons [6]. This is not peripheral advice, it goes to the heart of the mechanism.

– Be wary of anticholinergic medications. Many common medications, including some antihistamines, bladder medications, and older antidepressants, work by *blocking* acetylcholine receptors. Regular use of these drugs has been associated with increased dementia risk in some studies. If you are taking them, discuss alternatives with your doctor. This is the flip side of everything in this article.

– If you or someone you love is experiencing early memory concerns, early assessment matters. The integrity principle tells us that cholinergic treatments are most effective when started early [13]. The window of greatest benefit is precisely the period when most people have not yet sought assessment. Early cognitive concerns deserve early attention, not to catastrophise, but because early intervention, when it matters, genuinely changes outcomes.

– Stay engaged in the science. The next generation of cholinergic therapies, NGF delivery, receptor-targeted agonists, combination approaches, is actively in development [2][7]. The cholinergic hypothesis was the beginning of a story, not the end of one. The most important discoveries may still be ahead.

The journey from a post-mortem observation in 1976 to approved global therapies, precision imaging tools, and a new generation of investigational treatments is one of the great stories of modern neuroscience. It is a story of a field that looked honestly at what it found, followed the evidence where it led, and built something real. That is how science works at its best, and it is why this research, half a century on, still matters.

References

[1] The involvement of the cholinergic system in Alzheimer disease. (2025). https://pubmed.ncbi.nlm.nih.gov/40340068/

[2] NGF-based cholinergic therapies in Alzheimer disease. (2025). https://pubmed.ncbi.nlm.nih.gov/40340057/

[3] The Central Cholinergic Synapse: A Primer. (2025). DOI: 10.3390/ijms26199670 | https://pubmed.ncbi.nlm.nih.gov/41096935/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12524602/

[4] Cholinergic therapy in Alzheimer disease. (2025). https://pubmed.ncbi.nlm.nih.gov/40340059/

[5] Cognition and modulation of the cholinergic system. (2025). https://pubmed.ncbi.nlm.nih.gov/40340067/

[6] Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer’s Disease. (2024). https://pubmed.ncbi.nlm.nih.gov/38529600/

[7] Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer’s Disease. (2017). https://pubmed.ncbi.nlm.nih.gov/27697062/

[8] Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. (2008). https://pubmed.ncbi.nlm.nih.gov/18289004/

[9] Classics in Chemical Neuroscience: Donepezil. (2019). DOI: 10.1021/acschemneuro.8b00517 | https://pubmed.ncbi.nlm.nih.gov/30372021/

[10] Cognitive symptoms of Alzheimer’s disease: clinical management and prevention. (2019). DOI: 10.1136/bmj.l6217 | https://pubmed.ncbi.nlm.nih.gov/31810978/

[11] Cholinesterase as a Target for Drug Development in Alzheimer’s Disease. (2020). DOI: 10.1007/978-1-0716-0163-1_18 | https://pubmed.ncbi.nlm.nih.gov/31773661/

[12] Current pharmacotherapy for Alzheimer’s disease. (2006). DOI: 10.1146/annurev.med.57.121304.131442 | https://pubmed.ncbi.nlm.nih.gov/16409164/

[13] Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease. (2018). https://pubmed.ncbi.nlm.nih.gov/29309600/

[14] Cholinergic imaging in dementia spectrum disorders. (2016). https://pubmed.ncbi.nlm.nih.gov/26984612/

[15] Cholinesterase Inhibitors for Alzheimer’s Disease: Multitargeting Strategy Based on Anti-Alzheimer’s Drugs Repositioning. (2019). DOI: 10.2174/1381612825666191008103141 | https://pubmed.ncbi.nlm.nih.gov/31593530/

This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.